Kevin Lee, Ph.D., MBA (CEO)
Kevin Lee, Ph.D., MBA, is Chief Executive Officer of Bicycle Therapeutics. Under his leadership, Bicycle Therapeutics’ strategy has become focused on developing novel treatments for oncology using Bicycle Drug Conjugates® to selectively deliver toxins and other payloads to tumours. Dr. Lee joined Bicycle Therapeutics from Pfizer, where he served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s Rare Disease strategy, conceptualized and implemented the company’s Gene Therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GSK and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, Dr. Lee lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.
Dr. Lee studied Pharmaceutical Sciences at Nottingham University followed by a Ph.D. in Pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Dr. Lee is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick. Dr Lee is also the industry representative on the National Institute for Health Research (NIHR) Rare Disease translational research committee (TRC).
Ros Deegan, MBA (President and CBO, Bicycle Therapeutics Inc.)
Ros Deegan, MBA, is President and Chief Business Officer of Bicycle Therapeutics Inc., the U.S. subsidiary of Bicycle Therapeutics. Prior to joining Bicycle, Ms. Deegan most recently served on the senior leadership team at Trevena, Inc. as Senior Vice President, Business Development and Operations and previously held the role of Head of Finance and Operations. While at Trevena, she was responsible for start-up operations, negotiating a significant option and license agreement with Forest Laboratories, Inc., and leading finance and human resources through to the company’s first S-1 filing with the Securities and Exchange Commission. During her tenure, the company moved three programmes into the clinic, and raised over $200 million in private and public financings. Prior to joining Trevena, Ms. Deegan served as Director of Business Development at GSK in the U.S., leading transactions for the virtual immuno-inflammation group. Prior to that, she served as the Director of Operations for the Centre of Excellence for External Drug Discovery (CEEDD) and as Marketing Manager for GSK’s U.K. launch of Bonviva for post-menopausal osteoporosis and in Business Development.
Ms. Deegan holds a first-class degree from Cambridge University and received her MBA with distinction from INSEAD.
Nick Keen, Ph.D. (Chief Scientific Officer)
Nick Keen, Ph.D., is Chief Scientific Officer of Bicycle Therapeutics. He joined Bicycle from Novartis, where for the past five years he served as the Cambridge (US) head of oncology research. During his tenure at Novartis, Dr. Keen was responsible for leading research from basic target identification and drug discovery through to enabling early clinical trials. Under his leadership, the group delivered multiple new therapies to the clinic spanning the range from novel allosteric small molecule inhibitors of previously intractable targets, to advanced biologic therapies. His team was also responsible for publishing many basic discoveries in cancer biology, and for building industry leading platforms in whole genome scale target identification and in modelling the diversity of human clinical trials in mice.
Prior to his time at Novartis, Dr. Keen led the early lead generation group for oncology at AstraZeneca’s US research site with a particular focus on epigenetic regulation, and before this held positions of increasing responsibility in AstraZeneca’s UK oncology research group. During his time at AstraZeneca he delivered multiple agents to the clinic and was instrumental in the acquisition of KuDOS Pharmaceuticals leading to the registration of Olaparib (a first in class PARP inhibitor) for the treatment of BRCA mutant cancers.
Dr. Keen was an undergraduate at the University of Cambridge where he studied Natural Sciences, a graduate student with the ICRF in Cambridge and completed his post-doctoral studies at the Laboratory of Molecular Biology in Cambridge.
Maria Koehler, M.D., Ph.D. (Chief Medical Officer)
Maria Koehler, M.D., Ph.D., is Chief Medical Officer of Bicycle Therapeutics. She joined Bicycle from Pfizer, where she was Vice President of Strategy, Innovation and Collaborations for the Oncology Business Unit. At Pfizer, Dr. Koehler was a key member of the oncology leadership team responsible for creating and coordinating innovative strategies to bring cancer therapeutics from early-stage clinical trials to use on hospital floors around the world. Her accomplishments at Pfizer include leading development strategies for Palbociclib/IBRANCE, which was launched in 2015, and shaping the oncology portfolio.
Prior to joining Pfizer, Dr. Koehler was the Group Leader for the Medicine Development Center of GlaxoSmithKline Oncology, and a Senior Medical Director for Oncology Research and Development at AstraZeneca. During her academic career, she was the Clinical Director of Bone Marrow Transplantation at University Hospital in Pittsburgh, PA, and Director of the Bone Marrow Transplant Program and Associate Professor at St.Christopher’s Hospital in Philadelphia, PA. She is a Board Certified Hematology/Oncology physician, and the author of more than 160 peer reviewed publications and book chapters. Dr. Koehler received her M.D. and Ph.D. from the Silesian School of Medicine in Katowice, Poland.
Lee Kalowski, MBA (CFO)
Lee Kalowski is Chief Financial Officer of Bicycle Therapeutics. Prior to joining Bicycle, Mr. Kalowski served as the Chief Financial Officer of Tokai Pharmaceuticals, Inc., where he helped lead the company’s $105 million initial public offering in 2014. Previously, he was vice president, global biotechnology equity research at Credit Suisse, where he served as a senior research analyst covering the biotechnology sector. Before that, he worked in mergers and acquisitions in the pharmaceutical division of Johnson & Johnson and in global pharmaceutical equity research at Sanford C. Bernstein and Prudential Equity Group.
Mr. Kalowski received a B.A. in biology and economics from Union College and an MBA from The Wharton School of the University of Pennsylvania.
Michael Skynner, Ph.D. (VP Operations)
Michael Skynner, Ph.D., is Vice President of Operations at Bicycle Therapeutics. He joined Bicycle Therapeutics from Pfizer where he led rare disease efforts in Europe and founded and ran the Pfizer Rare Disease Consortium (RDC). The RDC was an innovative agreement between Pfizer and 20 leading U.K. universities that created research partnerships between Pfizer, academic researchers and patient groups to develop new therapies for rare and orphan diseases using a new collaborative paradigm. As part of those activities he also established Pfizer’s Genetic Medicine Institute, a bespoke research unit in central London embedded within the U.K. gene therapy academic community. Previously, he established a Discovery Performance Unit at GSK focused on developing therapeutics targeting inflammatory kinases using an externalised and partnered model with leading European biotechnology companies. In his time at GSK he successfully advanced multiple molecules from screening into clinical trials. Prior to GSK he co-founded a successful biotech start-up company, Cambridge Biotechnology Ltd (CBT), which specialised in developing small molecule and peptide therapeutics for inflammation and metabolic disease. CBT was sold to Swedish Orphan Biovitrum.
Dr. Skynner obtained his Ph.D. in Biochemistry at Imperial College and is an author on over 30 peer-reviewed scientific publications.
Gillian Langford, Ph.D. (VP Clinical and Therapeutics)
Gillian Langford, Ph.D, is Vice President of Clinical and Therapeutics at Bicycle Therapeutics and has over 20 years of drug development experience in both the pharmaceutical and biotechnology sectors. Dr. Langford joined Bicycle from Boyd Consultants, where she was Director of Programme Management, and was involved in working with European and North American companies developing oncology products and gene based medicines. Prior to joining Boyd Consultants, she worked at Alizyme Therapeutics and Ark Therapeutics where she was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (Phase 2 and 3). Dr. Langford was also employed by Imutran Ltd, a Novartis Pharma AG company, working in the field of xenotransplantation, initially as Unit Head of Molecular Biology and subsequently as Unit Head of Retroviral research where she was responsible for internal research projects and collaborations with academic groups.
Dr Langford graduated from Imperial College and obtained her Ph.D. in molecular biology at York University and is an author on over 35 scientific publications.
Peter U. Park, Ph.D. (VP Oncology)
Peter Park, Ph.D., is Vice President of Oncology Research at Bicycle Therapeutics Inc. Dr. Park brings over 14 years of oncology drug discovery experience in antibody and antibody-drug conjugate (ADC) therapeutics. Previously, he was Vice President of Biology at Mersana Therapeutics, Inc., where he co-invented and oversaw the discovery and development of novel Fleximer-based ADC, XMT-1522 and XMT-1536. He also led the joint research steering committee for the collaboration with Merck KgGA. Prior to that, Dr. Park served at ImmunoGen, Inc. in various roles, most recently as Senior Director of Discovery Research. In this role, he managed the discovery research portfolio for the development of novel monoclonal antibody and ADCs for the internal pipeline and for partners. He oversaw three departments that included Discovery Research, Antibody Engineering and Cell Line Development. At ImmunoGen, Dr. Park co-invented and advanced many clinical candidates, including Isatuximab (SAR650984), which was licensed to Sanofi and is currently in Phase 3 testing for multiple myeloma.
Dr. Park received his Ph.D. and B.S. in Biology from Massachusetts Institute of Technology.